59 North Communications
  • 59 North Communications
  • Quotes
  • Share:
  • Subscribe:
  • news.cision.com/
  • 59 North Communications/
  • Affibody’s licensee Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement/
  • David-Bejker-CEO Affibody

David-Bejker-CEO Affibody

Wed, Feb 18, 2026 14:28 CET

Low resolution

Medium resolution

Original resolution

Subscribe

Related Releases

Affibody Signs Letter of Intent with SHINE Technologies for Supply of Lutetium-177 Thu, Feb 19, 2026 23:33 CET
©Cision
Privacy statement | Cookies | About | Content Policy | Contact    Cision
©Cision Privacy statement Cookies About Content Policy Contact

   Cision